Tiziana Life Sciences PLC's (NASDAQ:TLSA) (LON:TILS) Dr Kunwar Shailubhai discusses with Proactive's Andrew Scott the positive data from its clinical study of nasally administered Foralumab in COVID-19 patients in Brazil. He says CT scans of the lungs showed the improvement was approximately double that shown in patients treated with Foralumab as compared to those in the control group and medical records of patients also showed a more rapid recovery in senses of smell and taste in Foralumab treated patients, as compared to those in the control group.
Tiziana Life Sciences reports strong topline data from Foralumab COVID-19 trial
